Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Source: 
Fierce Biotech
snippet: 

GLP-1 (glucagon-like peptide-1) receptor agonists make up a well-established class of treatment for Type 2 diabetes. AstraZeneca’s Byetta and Bydureon, Novo Nordisk’s Victoza and Ozempic, and Eli Lilly’s Trulicity all belong to this family. Because of their possible actions on nerve cells, scientists are now exploring the potential of GLP-1 receptor agonists in treating neurodegenerative diseases.